Showing results (101-110 of 174) with videos related to

Sort By:
Pageof 18
Emerging Infectious Diseases|May 8, 2007
Pneumocystis pneumonia in HIV-positive adults, MalawiJoep J G van Oosterhout, Miriam K Laufer, M Arantza Perez, et al.
Plos Medicine|March 16, 2007
Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in MaliShannon L Takala, Drissa Coulibaly, Mahamadou A Thera, et al.
Malaria Journal|September 8, 2007
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malariaChristopher V Plowe, Cally Roper, John W Barnwell, et al.
Malaria Journal|September 8, 2007
World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugsRic N Price, Grant Dorsey, Elizabeth A Ashley, et al.
The American Journal of Tropical Medicine and Hygiene|July 27, 2022
Serologic and Cytokine Profiles of Children with Concurrent Cerebral Malaria and Severe Malarial Anemia Are Distinct from Other Subtypes of Severe MalariaRafal S Sobota, Abby R Goron, Andrea A Berry, et al.
Trials|July 20, 2016
TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trialMatthew B Laurens, Randy G Mungwira, Osward M Nyirenda, et al.
Plos Medicine|February 12, 2011
A research agenda to underpin malaria eradicationPedro L Alonso, Graham Brown, Myriam Arevalo-Herrera, et al.
The American Journal of Tropical Medicine and Hygiene|December 26, 2003
Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malariaAbdoulaye A Djimdé, Ogobara K Doumbo, Ousmane Traore, et al.
The Journal of Infectious Diseases|January 25, 2002
Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malariaJames G Kublin, Fraction K Dzinjalamala, Deborah D Kamwendo, et al.
Vaccine|June 24, 2020
Epitope-based sieve analysis of Plasmodium falciparum sequences from a FMP2.1/AS02<sub>A</sub> vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variantsAmed Ouattara, Amadou Niangaly, Matthew Adams, et al.
Pageof 18